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Abstract
THOMAS ANGUELLA
SYNTHESIS AND IDENTIFICATION OF AN INVESTIGATIONAL ESSENTIAL
PRECURSOR COMPOUND FOR THE PURPOSE OF THE DEVELOPMENT OF A
VACCINE TREATMENT AGAINST THE PEANUT ALLERGY
2016-2017
Catherine Yang, Ph.D.
Master of Science in Pharmaceutical Sciences

Presented in this master’s thesis are several studies carried out to determine the
viability of several allergoid candidates utilizing the major peanut allergen Ara h 2. The
Ara h 2 allergen protein appears naturally as a doublet when observed by gel
electrophoresis, SDS-PAGE. Optimization of allergen purification methods successfully
led to Ara h 2 purity, and the ability to standardize procedures to yield consistently pure
samples. The purified allergen was chemically crosslinked with diketone derivatives
selected for their abilities to react with specific amino acids accessible on the Ara h 2
protein. Chemically modified allergen samples were also evaluated using SDS-PAGE;
successful protein modifications were identified by doublet band smearing or even
oligomer formations such as dimers and trimers. Immunoassays were then applied to
determine if epitope surface region is disrupted to indicate the diminished immune
responsiveness to the modified allergen. Ara h 2 IgE specific antibodies, through western
blot analysis, were used to determine antibody affinity between chemically modified and
unmodified allergen proteins and to characterize any differences between the allergen
samples. Results indicate that Ara h 2 may be chemically crosslinked using functional
active reagents and that is possible to chemically shield IgE epitope surface regions after
modification.
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Chapter 1
Introduction
Significance of Peanut Allergies
Food allergies are a major health concern for patients and for the healthcare
providers who are tasked with the responsibility to treat them, because of the rapid onset
and limited treatment options available in case of emergency. Currently, 8 foods are
associated with food related allergies because of the immune reaction they have the
potential to elicit in allergic individuals1. Food allergies are prevalent in the developed
world, with more than 2% of the adult population (nearly 5.5 million Americans)
estimated to suffer from them2. However, peanuts are especially disconcerting because of
the low potential for patient to outgrow the condition. Common allergies to foods are
likely to be outgrown or tolerated once the patient reaches adulthood, however an allergy
to peanuts is not ameliorated with age and is virtually a life-long condition3. Peanut
allergies are severe because they can sometime cause death almost immediately due to
fatal anaphylaxis4. Widespread application and use of peanuts throughout the world pose
an inescapable risk to patients, currently no preemptive treatments exist but to avoid
exposure to peanuts altogether. Among all allergies, a peanut allergy is the most severe
and widespread. It is believed that 1.3% of the adult American population and 0.5% of
children under 4 years old currently suffer from allergies to peanuts2.
IgE antibodies have an important role in allergic responses within the body. These
antibodies are significant because, in the presence of an allergen, they promote mast cell
degranulation. The observed symptoms of an allergic reaction are the results of mast cell
1

degranulation in the body. Degranulation is the term given when mast cells release
mediator molecules such as leukotrienes, prostaglandins, and histamines5, 6. The medical
condition used to define a severe allergic reaction is anaphylaxis. Anaphylaxis is
characterized as an over exaggerated immune response as the body’s chief reaction
towards the presence of the absorption of food allergen proteins6. Food induced
anaphylaxis can occur within only a few minutes after exposure. Anaphylaxis is a
medical emergency that requires treatment usually with an epinephrine injector possibly
followed by several doses of steroid medications - it is often necessary for the patient to
visit the emergency room as well for evaluation6. Food-induced anaphylaxis is a lifethreatening condition where exposed, allergic individuals experience symptoms targeted
toward single or even multiple body systems and can lead the system to be severely
compromised as a result6. Symptoms of anaphylaxis can be localized but eventually
become pervasive and detrimental as time passes without treatment. Patients who are
unlucky enough to come into contact with their allergen (complete ingestion not always
necessary to provoke a response) experience a rapid onset of symptoms that lead to
immediate health decline and, if untreated, sudden death. Localized symptoms include
gastrointestinal pain as a result of inflammation of the GI tract, difficulty breathing or
difficulty getting enough air into the lungs usually caused by airway organs becoming
constricted and closed off - this is usually identified by healthcare providers if wheezing
is present6. Other noticeable symptoms include rash; swelling of the face, extremities, or
other areas of the body; or a severe drop in blood pressure resulting in dizziness
eventually resulting in the patient losing consciousness5.
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Immunoglobulin E (IgE) and Immunoglobulin G (IgG) antibodies are specifically
important in the discussion of peanut allergies because of their allergen binding affinities
and for the roles they play in eliciting an over exaggerated immune response. Binding
affinity of IgE antibody to a specific allergen is directly related to the occurrence of an
allergic episode in the presence of the allergen protein. An allergen that is bound to IgE
antibodies almost instantly produces an immune response and symptoms consistent with
anaphylaxis and anaphylactic shock5. Allergen sensitivity, the body’s overall sensitivity
to an allergen and likelihood of producing an allergic episode, is understood to be directly
related to the quantity of IgE specific antibodies currently within the body7. It is believed
that IgG antibodies do not play a role in eliciting an allergic attack but are just as
sensitive to the allergens compared with IgE antibodies. IgG antibodies act to safely and
effectively remove the peanut allergen from the body without eliciting an allergic
response. Other components and functions of the immune system exist that aid in
desensitization, however the exact mechanism is not well understood5, 6.
The following cascade comes from the current understanding of allergen immune
reactions: upon exposure, an allergen enters the body and immediately comes into contact
with the dendritic cell prior to promoting TH0 cell conversion8. TH0 cells are converted
by the allergen activated dendritic cells. TH0 cells are converted into either TH1 or TH2
cells, depending on which cell differentiates the TH1 or TH2 cells then travel to the B
cells. The B cells then produce either IgG or IgE antibodies. TH2 cells produce IgE
antibodies, TH1 cells produce IgG antibodies8. Mast cells are also important because they
produce the usual immune response as well as the symptoms commonly associated with
allergic reactions. The specific role mast cells have in producing an allergic response is
3

still not completely understood, but there is an evidence to support the presence of IgE
receptors on the surfaces of mast cells, which when activated by allergen linked IgE
allow the mast cells to produce histamines, prostaglandins, leukotrienes, and cytokines.
In other words, when IgE antibodies are reacted with an allergen, antibodies can then
bind to the membrane receptors on the surface of the mast cells which leads to a reaction
cascade within mast cells leading to degranulation5, 6, 8. Degranulation is the process by
which mast cells release mediator molecules into the extracellular space. When the
mediator molecules come into contact with membranes of nearby cells and tissues the
cells undergo self-destructive reactions usually local apoptosis directly resulting in
irritation persistent in the region of the body where the reaction occurred5, 6, 8. There are a
few other degradation pathways not discussed here that carry out immune responses to
allergens, but the pathway described above is the most significant and potentially lethal to
patients.
When the allergen enters the body the cross-linking of allergens to receptor bound
IgE occurs and this is one of the leading causes for mast cell degranulation.
Degranulation occurs when the mast cell releases prostaglandins, cytokines, histamines,
and leukotrienes into the body; collectively these are known as mediator molecules.
When nearby cells come into contact with these mediator molecules they can undergo
apoptosis which leads to physiological symptoms of allergies e.g. difficulty breathing due
to apoptosis of bronchial epithelial cells. The receptor FcyRIIB is known to crosslink
receptor bound IgE with allergens, however this receptor is also known to crosslink
allergen bound IgG as well Burton9. IgG is an antibody molecule that has the ability to
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compete with IgE for binding and in cases where IgG is present there is less binding of
IgE5, 6, 8.
Unfortunately, it is possible for patients to suffer from polysensitization in which
multiple cross reactions occur increasing the severity and even the occurrence of an
allergic reaction. In other words, Ara h 2 sensitized antibodies are also known to cross
react with different additional allergens therefore increasing the probability of a reaction
if the patient is exposed to peanuts in general. Reactions to Ara h 1 and/or Ara h 3
antigens in addition to Ara h 2 are typically predictive of more severe allergic reactions10,
11

.
Aside from allergenicity, allergens also have antigenicity that can be disrupted,

usually referred to as immunogenicity. Immunogenicity is the ability to recognize an
allergen as a foreign substance, this is not the same as allergenicity because
immunogenicity is not always associated with production of an allergic response12. If an
allergen produces an immune response but loses the ability to produce an allergenic
response then tolerance towards the allergen can be promoted without the threat of
anaphylaxis. This can be achieved through chemical, mechanical, or even with the use of
radiation (e.g. microwave)13,

14, 15, 16

. By definition this is referred to as an allergoid,

which is an antigen with reduced allergenicity and maintained immunogenicity17. An
allergoid could be an essential component making up a potential vaccine designed to be
exposed to patients. The synthesis and characterization of a viable allergoid is the first
step in the development of an effective and safe vaccine to promote tolerance in patients
with peanut allergies. Physical disruptions to allergen IgE epitopes can lead to decreased
antigenicity12.
5

IgE epitopes on the surface of peanut allergen proteins, like those present on the
surface of Ara h 2, can become disrupted through chemical modification and could result
in a lower affinity or complete loss of affinity to IgE sensitive antibodies18.
Circumventing IgE binding could result in an increase in the degradation pathways
responsible for digesting peanut allergens without harmful symptoms. This understanding
is consistent with the findings of a clinical study where 21.5% of peanut allergic patients
outgrew their condition after peanut challenges administered to patients with already low
peanut IgE levels in the blood19. Peanut allergies are harmful to hypersensitive patients
because of the major allergen protein, Ara h 2, and its resistance to chemical modification
within the body. If the proper conditions are determined, chemically modifying the
peanut allergen protein could be a simple and effective technique to develop a treatment
for peanut allergies.
Currently, the only treatments available are post-occurrence treatments, which are
usually given to patients after they are exposed to the allergen and the allergen is already
ingested. Unless a pre-reaction treatment is developed, healthcare providers are limited to
only emergency treatments given after allergen exposure and advising patients to abstain
from peanuts altogether - and that’s it. Proper prevention is the only definitive measure to
lower the possibility of an allergic reaction to peanuts. Avoiding peanut products
altogether is currently the only guaranteed way to prevent an allergic reaction. Patients
need to develop an alertness against foods that could contain peanuts to avoid
accidentally exposing themselves to the allergen. Patients are often burdened with this
condition because of the required vigilance needed of them in questioning how
everything they eat is prepared (e.g. when going out to dinner the allergic patron may
6

need to be reassured by the chef who prepared the meal of the absence of any remnants of
peanut products). Care plans are often needed to be prepared in the event of an exposure
to the allergen. The care plan is needed to be understood by anyone who is looking after
an allergic child or even an allergic adult. Caring for a child who is allergic to peanuts is
a large responsibility and requires guardians to ensure the child understands their own
emergency plan and what to do in the event of an emergency, in most cases remaining
calm is the best way to care for someone having an allergic reaction (if adrenaline is
unavailable) before advanced help arrives. It is also usually recommended by healthcare
providers that allergic individuals wear a medical emergency identification bracelet or
necklace so that lay responders can be aware of their condition in the event of an
exposure.
Even strict avoidance to peanuts is difficult, most of the time the ingestion is
accidental. Allergic individuals always live in fear of accidental exposure and the
possibility of a server allergic reaction. Patients with peanut allergies or any other food
allergies are usually not limited to being allergic to one allergen e.g. peanuts, in fact they
commonly have allergies to a whole host of tree nuts such almonds and walnuts (for
peanut allergies). Therefore, the patient needs to avoid related foods as well as the
specific allergy food.
Areas of Research
Peanut allergies are concerning because public health related research shows a
significant increase in prevalence of these allergies within the U.S. over the last decade20.
Unfortunately, the exact cause for an individual to become sensitized (allergic) to peanuts
is not completely understood, however there are several literature supported theories
7

available. There is evidence supporting the proposition that patient sensitization occurs at
a young age as a result of breastfeeding using milk containing trace amounts of allergen
proteins7,

21, 22

. As a rationale to this sensitization theory Jarrett E E.21 hypothesized

stimulation of helper T cells promotes IgE production, occurring in the presence of low
initial antigen doses compared to high initial antigen doses in which case she
hypothesized the antigen would actually stimulate suppressor T-cells inhibiting IgE
production. Coupled with this theory, the research by Hourihane et al.23 helps explain the
increased prevalence of peanut allergies in westernized countries. Although their study
did not control for recall bias, the mothers of children allergic to peanuts and age 5 years
old or younger were significantly more likely than mothers of older children to have
eaten peanuts regularly while pregnant or breastfeeding23. The increasing trend for
mothers to consume peanuts while pregnant shouldn't be overlooked since it directly
correlates with the outcome of having a child sensitized to peanuts (prior to their first
peanut exposure) and also correlates with the overall increase in number of patients
allergic to peanuts.
Currently, allergen-specific immunotherapy (SIT) is the only treatment able to
cure allergic diseases and has been shown to be successful in treatment of insect venom
allergy and in patients suffering from allergic rhinitis or rhinoconjunctivitis24.
Immunotherapy treatments are well supported and understood, however desensitizing
patients to a dangerous allergen poses a threat to the patient’s safety that cannot be
overlooked. Desensitizing patients to a dangerous allergen (i.e. no longer sensitized to the
antigen) needs to be a careful process. Jarret’s theory proposes that exposing patients to
substantial allergen quantities stimulates suppressor T-cells within the body, and
8

promotes desensitization. This theory is consistent with the outcome of patients who were
treated with allergen specific immunotherapy using insect venom allergens which
ultimately lead to a cure of the allergy24. However, a method to safely expose patients to
large quantities of otherwise harmful peanut allergens is not well understood and requires
further exploration.
Among the research conducted around peanut allergies, a group of Australian
researchers identified a type of oral immunotherapy that was effective in treating children
with peanut allergies. Probiotic and peanut oral immunotherapy (PPOIT) was effective in
inducing possible sustained unresponsiveness and immune changes that suggest
modulation of the peanut-specific immune response in children with peanut allergy25. 62
children, as a part of a clinical study, were exposed over a duration of 18 months to a
minimal amount of peanut protein sample daily that also contained the probiotic
lactobacillus rhamnose, in extremely high quantities. Remarkably the research concluded
that over 80% of the study participants achieved possible sustained unresponsiveness to
peanuts25. The probiotic was believed to have aided the immune system in developing a
protective response preventing the usual aggravated allergic response25. This altered
immune response to the peanut protein presents potential investigational treatments of
peanut allergies and could lead to the development of an overall cure. However, the
modified allergen has not been evaluated yet for prolonged effectiveness so the return of
usual symptoms still remains a possible concern to be studied25.
Major peanut allergen protein Ara h 2 has been observed to produce severe
allergic responses when exposed to endogenous antibodies26,

27

. Life-threatening

conditions such as anaphylaxis could be the result in allergic individuals who are not
9

treated immediately after exposure to this specific allergen6. Currently, there is little that
can be done to preemptively treat allergic episodes resulting from peanut allergens.
Identifying a safe, and preferably uncomplicated, method of exposing patients to the
peanut allergen to increase the body’s tolerance to the allergen is significant to increasing
understanding and in the overall treatment of these allergies. More research is also
necessary to increase understanding of the chemical properties of Ara h 2 and its role in
eliciting an allergic response by the body.
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Chapter 2
Major Peanut Allergen Ara h 2 Isolation and Identification
Ara h 2 is one of the known allergens in peanuts that causes the most severe
reactions associated with peanut allergies. The peanut kernel contains 11 major allergen
proteins that on their own elicit an allergic response27. Of the 11 peanut allergens, Ara h 2
has consistently shown to be the most significant. More than 90% of patients with peanut
related allergies contain IgE antibodies with remarkably high binding affinity to Ara h
227. Ara h 2 has also shown to be seemingly resistant to most protein degradative
processes. For example, heating Ara h 2 actually increases its ability to elicit an allergic
response within the body, and exposing Ara h 2 to conditions consistent with the stomach
and GI tract showed to have little to no effect on reducing the protein's overall
allergenicity28, 29, 30, 31, 32.
Ara h 2 appears on SDS-PAGE as a doublet with a molecular weight between 1719kDa. Ara h 2 is an allergen protein that is made up of 157 amino acids Figure 133.
Isolating Ara h 2 is the essential initial step in the synthesis of the potential allergoid.
However, prior to immunoassays, experiments designed to observe the presence of
structural changes to the allergen are needed. To perform experiments focused on the
structure of Ara h 2, isolating Ara h 2 is important to avoid the presence of additional
proteins in solution that could lead to variable results. A robust, reliable, and efficient
method for purifying Ara h 2 is important for developing and screening crosslinking
conditions.

11

Figure 1. Ara h 2 amino acid sequence. Ara h 2 amino acid sequence represented as
single letter amino acid code Burks33.

Synthesizing an allergoid from Ara h 2 is the major objective of this research
followed by characterizing its in-vitro immune affinity prior to in-vivo immunoassays. In
addition to in-vitro experiments, reproducing the allergoid synthesis reaction is a strong
factor in determining whether or not the product is ready to be exposed to biological
subjects (small and large animals). Exposing animal subjects requires highly pure
12

allergoid samples. For example, if impurities do exist as an essential factor to the
formation of the allergoid then reproducing the allergoid reaction would not be possible
without the presence of the original impurity, even if impurities existed that do not
benefit the overall allergoid reaction there is still potential for the impurity to alter the
overall effectiveness of the product as a drug once administered to subjects leading to
unpredictable and even dangerous outcomes. The most effective method for producing an
allergoid consistently, that displays no uncertainty in usability and effectiveness, remains
contingent on how well the synthesis reagents were isolated.
Materials and Methods
Sample Preparation
Ara h 2 was purified following the method by Sen34 with additional modifications
made to the procedure. Peanut kernels (Arachis hypogaea L., Florunner cultivar)
purchased from Good Earth Peanut company were exposed to liquid nitrogen and the
frozen kernels were then crushed by mortar and pestle prior to being defatted three times
in a Soxhlet extractor starting with petroleum ether for the first two exchanges and then
finally using chloroform for the last reflux. The defatted peanut kernels were pulverized
to a fine flour. The defatted peanut flour was then added to a TBS buffer (pH 8.3, 65 mM
Tris-base, 1 mM EDTA, 1 mM PMSF and 200 mM NaCl) and stirred in TBS for 1 hour
on ice at 4° C. After stirring the peanut powder in the TBS buffer for about 5 minutes, the
extract was sonicated (Sonics Vibra-Cell VCX-600) at 40% for 2 min over ice to increase
the chances of extracting intracellular proteins into the sample solution, through nonionizing vibration. The extract was then cleared by filtration through six layers of
cheesecloth and then centrifugation at 30,000 × g for 30 min at 4° C. Ammonium sulfate
13

was used to fraction the supernatant. Ammonium sulfate was added to bring the solution
to 40% saturation, the sample was then centrifuged at 30,000 × g for 30 min at 4° C and
the supernatant was collected and the pellet was discarded. Ammonium sulfate was added
again to bring the solution to 70% saturation and the sample was centrifuged at 30,000 ×
g for 30 min at 4° C and the pellets was collected and the supernatant was discarded. The
pellets were resuspended in a total of 10 mL of TBS buffer (pH 8.3, 65 mM Tris-base, 1
mM EDTA, 1 mM PMSF) and sonicated on ice for 20 seconds at 39% power.
Undissolved particles were removed by centrifugation (3,000 × g for 15 min).
Allergen purification was accomplished using a series of chromatography
columns based on ionic charge and hydrophobicity. Q-sepharose column prepared with
100mL of resin to achieve the desired column bed volume of 2.5cm X 30cm. The protein
sample was applied to the Q-sepharose anion exchange column which was equilibrated
with pH 8.3 65 mM Tris buffer, 1 mM EDTA and1 mM PMSF prior to loading protein
sample. After washing the column with 200 mL of Tris buffer containing 40 mM NaCl,
bound proteins were eluted using a 400 mL linear salt gradient (40 mM - 500 mM NaCl,
65 mM Tris-HCl, 1 mM EDTA, 1 mM PMSF at pH 8.3) at 2 mL/min flow rate. 2.5 ml
fractions were collected, analyzed with coomassie dye 50uL: 150uL (protein: dye) and
then analyzed by SDS-PAGE. Pooled fractions containing Ara h 2 were dialyzed
overnight at 4°C against 15 mM ammonium bicarbonate (pH 7.0) dialysis buffer
exchanged 3-5 times. After dialysis, aliquots were lyophilized and stored at −70°C until
needed.
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SDS-PAGE Procedure
Samples solubilized in sample loading buffer (1.5 mL of pH 6.8, 1 M Tris-HCl,
1.5 mL of 1 M dithiothreitol, 0.3 g of sodium dodecyl sulfate, 0.015 g of bromophenol
blue, 1.2 mL of glycerol - Final volume of 7.5mL). Samples solubilized by combining
10uL of 40% diluted sample (dilution with 25mM Tris buffer at pH 10.5) with 10uL of
2X sample buffer. Samples vortexed slowly, to avoid splashing, and then were heated in
boiling water (100° C) for 5 minutes. Samples were vortexed on setting number 8 (after
heating) and centrifuged at 3,000 × g for 5-10 seconds at room temperature (to
accumulate sample toward the bottom of the centrifuge tube, and away from the container
walls) prior to loading samples onto SDS-PAGE gel. Tris glycine (4-20%) SDS-PAGE
gels (manufactured by BioRad) were used. A 10uL of sample volume was loaded into
each well of the SDS-PAGE gel. A 10uL of molecular weight standard was loaded onto
the gel only after protein samples were loaded. The gel was allowed to run at 120V until
enough time passed for the proteins to run to the bottom of the gel. The gel was then
stained in a coomassie dye and methanol based staining solution (1.25g Coomassie R250, 30% methanol, and 10% acetic acid). After approximately 24 hours in the staining
solution, the gel was then destained to remove excess stain using a water based destaining
solution (30% methanol and 10% acetic acid).
Results
Prior to running samples on SDS-PAGE, samples were evaluated for protein
content by commassie dye analysis. Results using coomassie dye can be found in Figure
2 and Figure 3. Figure 2 and Figure 3 compare the results of different salt concentrations
in preparing the protein elution gradients. Figure 2 shows the result of running a strong
15

elution gradient of 40mM – 1M NaCl (200mL) and resulted in eluted proteins being
heavily concentrated in the middle of the gradient. Whereas Figure 3 displays elution
results after running a gradient of 40mM – 140mM NaCl (200mL) it appears to suggest a
larger dispersion of eluted proteins compared to Figure 2.

16

Indicates where Ara h 2 major allergen
was found.
Figure 2. Coomassie dye analysis of fractions following the Q-column, eluted with 40
mM – 1 M NaCl gradient at 2mL/min 2mL fraction volume (65 mM Tris buffer, 1 mM
EDTA, and 1 mM PMSF). Every 3rd sample out of 144 total collected samples was
aliquoted starting in well 1A moving to the right. e.g. 2A corresponds to fraction # 9.

17

Indicates where Ara h 2 major allergen
was found.
Figure 3. Coomassie dye analysis of fractions following the Q-column, eluted with 40 140mM NaCl gradient @ 2mL/min 2mL fraction volume (65 mM Tris buffer, 1 mM
EDTA, and 1 mM PMSF). Every 3rd sample out of 144 total collected samples was
aliquoted starting in well 1A moving to the right. e.g. 2A corresponds to fraction # 9.

18

Discussion of Allergen Purification
According to Sen34 defatting peanut kernels can be achieved by refluxing petroleum ether
over the sample. According to Packer35 defatting samples not completely can result in
poor extraction efficiency. Therefore, this step was modified, petroleum ether was used to
start, which has a polarity index of 0.1, but ultimately the reflux was finished with
chloroform that has a polarity index of 4.1 to extract less non-polar materials away from
the peanut kernels. Following ammonium sulfate precipitation pellets should be dissolved
completely to allow for complete separation. Our findings led us to determine that 40
mM – 500 mM NaCl was the optimal gradient to be used for Ara h 2 elution from the Qsepharose column observed by commassie dye analysis (Figure 4) and SDS-PAGE
analysis (Figure 5). This determination was made because of the inefficiency in eluting a
mixture of unseparated proteins all at once (Figure 2) and in eluting the desired proteins
too widely to be efficiently collected (Figure 3). Gradients that contained larger or
smaller margins between concentrations of NaCl, than described above, were generally
not well suited and caused inconclusive and inconsistent results. Also, to be noted, since
Ara h 2 is only 17kDa in size, 4-20% Tris-glycine gradient gels (manufactured by
BioRad) were used for precise separation of protein. Other gradient gels were not
individually studied since additional gradient gels were not well documented by the
literature for use in the separation of peanut allergen proteins.

19

Indicates where Ara h 2 major allergen
was found.
Figure 4. Coomassie dye analysis of all 144 fractions after running sample on Qsepharose column eluted at 40 - 500 mM NaCl, 65 mM Tris buffer, 1 mM EDTA, and 1
mM PMSF. Well # 1 (1st fraction) located in top left well. Red lines are indicative Ara h
2 protein.
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Figure 5. SDS-PAGE gel of specified fractions, which indicated protein after using
coomassie dye, of sample after running sample on the Q-sepharose column eluted at 40 500 mM NaCl, 65 mM Tris buffer, 1 mM EDTA, and 1 mM PMSF.
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Chapter 3
Protein Chemical Modification-Lead Compound Assessment
The major peanut allergens Ara h 2 and Ara h 6 were the focus of the research
study completed by Koppelman29 because of the apparent synergy of these allergens in
eliciting an allergic response. Researchers confirmed Ara h 2 and Ara h 6 have an integral
role in the biological mechanism leading to an allergic reaction, however, by reducing the
allergens and subsequently chemically modifying [alkylating] them with glutaraldehyde
the researchers determined that it was possible to alter the allergen’s secondary and
tertiary structures. Presuming allergen structure was necessary to allergen function,
researchers designed a series of clinical studies to further evaluate the newly, chemically
synthesized allergen products. Again, using children as participants, patients were
injected with small doses of the chemically modified allergen sample. The participants
exposed to the chemically modified samples displayed later time activated reactions and
overall decreased response when exposed to the native allergens. The researchers
concluded this to be a viable method in desensitizing patients to their allergen and
because of the levels of effectiveness observed should serve as another potential
candidate for peanut allergy therapy. This finding (glutaraldehyde being a necessary
protein modifier) was also identified by Park36; Silva37; and Stanić-Vučinić38 however
these groups of researchers experimented with proteins and allergens outside of Ara h 2.
Proteins can crosslink through glycation reactions, and undergo physical
structural changes39,

40, 41

. Carbonyl containing reagents were previously identified as

capable of eliciting protein cross-linking. According to Acharya42 the protein RNase was
successfully cross-linked using glyceraldehyde. The experiment called for 20 mM of
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glyceraldehyde at 7.4 pH and 37° C. The formation of crosslinks with RNase using
glyceraldehyde was concluded to be analogous to nonenzymic glycation reactions. In
other words, by using (carbonyl containing) aldehydes it is possible to form advanced
glycation end products i.e. cross-linked structural proteins Acharya42.
There are several studies in the literature that can be referred to for support where
several reagents were evaluated for success in modifying Ara h 2 and in eliminating or at
least significantly reducing allergenicity. Experiments conducted by Chung43 displayed
significant decrease in allergenicity of peanut allergens using phenolic compounds.
According to Chung44 tannic acid is successful at significantly reducing allergenicity of
peanut allergens. One study actually concluded that using ferulic acid actually increases
the likelihood of Ara h 2 antibody binding45.
According to Chung46 caffeic acid and chlorogenic acid are examples of chemical
reagents that can be oxidized to form quinone derivatives susceptible to bonding to free
amine groups, sulfhydryl groups, and tryptophan groups and capable of catalyzing a
crosslink between two separate complete proteins. Caffeic acid and chlorogenic acid have
been studied for their potential to modify the allergen protein and have successfully
formed Ara h 2 allergoids. From the experiments carried out by Chung46 oxidizing caffeic
acid require a basic environment above pH 10 to form the reactive quinone necessary to
potentiate the crosslinking reaction. Caffeic acid and chlorogenic acid are just two
examples of chemical modification reagents, where it is important the proteins being
crosslinked are examined for the appropriate amino acid content needed to catalyze the
reaction. Since these chemical reagents were found to be successful by Chung46 we
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proposed the possibility of reagents closely related to these molecules also containing
potential reactivity with Ara h 2 as well.
Proteins capable of crosslinking reactions, catalyzed by arginine targeting
chemical reagents, contain roughly 5% arginine residues47. The quantity of arginine
residues in Ara h 2 is approximately 12%33. The ketone aldehyde group of the compound
Phenylglyoxal acts as an oxidizing agent and targets arginine residues in proteins48. The
guanidine group of arginine interacts with phenylglyoxal and forms heterocyclic
condensation products which could potentially promote a structural change to occur in
Ara h 2 which results in the crosslinking between two reactive Ara h 2 proteins48.
Diketone reacting groups of aromatic molecules also react well with arginine amino acids
and have been studied to promote crosslinking in proteins. Based on this understanding,
the compounds phenylglyoxal monohydrate and its derivatives4-fluorophenylglyoxal
hydrate,

4-methoxyphenylgyoxal

hydrate,

2,3-butandione,

2,3-hexandione,

3,4-

hexanedione, and 2,3-heptanedione were examined to determine their ability and
efficiency in crosslinking Ara h 2. Figure 11 shows a highly simplified proposed reaction
mechanism that utilizes arginine residues of Ara h 2 to promote a crosslinking reaction to
occur.
Materials and Methods
Chemically Crosslinking Ara h 2
Allergoid synthesis reactions were prepared in sealed 1.5 mL centrifuge tubes.
The cone shaped centrifuge tubes allowed reaction mixture to pool near the base of the
container for simple extraction by micropipette. Allergoid synthesis reagents were
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dissolved in 25 mM Tris-base buffer at pH 10.5, using additional solvents when needed
(Figure 9) and serial diluted to desired concentrations.
Lyophilized protein was dissolved into 25 mM Tris buffer at pH 10.5 at a working
protein concentration of approximately 1-2 mg/mL. Ara h 2 protein concentration was
quantified against a BSA (bovine serum albumin) standard curve. To prepare the BSA
standard curve the following BSA dilutions were prepared (according to the manufacturer
ThermoFisher Scientific): 2000, 1500, 1000, 750, 500, 250, 125, and 25ug/mL, and
0ng/mL for blank control. The BSA dilutions were prepared using 25 mM Tris-base
buffer at 10.5 pH (same buffer used to dissolve Ara h 2). 5uL of each BSA stock dilution
was added to the appropriate well on a 96-well microplate. BSA stock dilutions were
added to the microplate, three trial replicates evaluated. A 5uL of the unknown
concentration of Ara h 2 sample was added to 3 clean wells on the microplate (three trial
replicates evaluated). 250uL of the coomassie dye reagent was then added to each well
containing unknown or stock samples and the microplate was allowed to mix on shaker
for 30 seconds prior to measuring absorbance. Stock and unknown absorbance was read
with a microplate reader using UV-visible light at 595 nm wavelength. The average
absorbance at 595 nm for each BSA standard dilution vs. its concentration in ug/mL was
plotted after correcting for the blank (0ng/mL concentration) for each concentration. The
BSA standard curve was then used to determine the protein concentration of the unknown
Ara h 2 sample.
Stock solutions of the modifying reagents were prepared using buffer and any
additional solvent(s) necessary to dissolve the specific reagent. The desired
concentrations for the stock solutions were prepared by serial dilution making sure to
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keep the overall solvent concentration consistent for each reagent concentration. Once
stock reagent solutions were prepared, stock Ara h 2 solutions were prepared using
2mg/mL protein concentration (1mg/mL final protein concentration after reaction).
Finally, we combined the stock reagents with the Ara h 2 solution by adding an aliquot of
each stock concentration into the tube already containing Ara h 2 protein (equal volume
to volume ratio). The centrifuge tubes were then sealed off and incubated at the
conditions described above. A graphic of the modification procedure can be found in
Figure 6.
Several reagents were evaluated for allergoid synthesis potential (Table 2 and
Table 3). The evaluated reagents were reacted with Ara h 2 under various conditions to
determine reaction viability. The evaluated conditions included variations in reaction
buffer, reaction buffer pH, exposing the reaction mixture to agitation vs. non-agitation,
reaction temperature, concentration of reagent exposed to protein, and time exposed to
protein evaluated to understand which conditions were ultimately most effective in
forming an allergoid (Table 1).
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Figure 6. 3-step infographic procedure used to chemically modify the allergen.
Depending on the reagent used specific solvents were required to fully dissolve the
reagent into solution. Following the solvent concentration guidelines listed above for the
specific reagent to be dissolved. It is necessary to keep the solvent concentration
consistent for all reagent serial dilutions. The highest reagent concentration to be
evaluated was determined and then multiplied by two because the prepared stock
concentrations are actually 2X that of the prepared working concentrations. 1mL of
solvent/buffer solution was used to prepare the first reagent concentration within a 1.5
mL centrifuge tube then vortexed until reagent dissolved completely. Serial dilutions of
first reagent concentration prepared by adding 500 uL of solvent/buffer to 5-10 empty 1.5
mL centrifuge tubes. 500 uL of original reagent solution was combined with
solvent/buffer within one of the prepared centrifuge tubes and mixed until homogeneous.
Samples were prepared by a 2-fold serial dilution to create several stock reagent
solutions.
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Table 1
Evaluated Ara h 2 allergoid synthesis reaction conditions
Conditions
Reaction
Temperature

4° C

20° C

37° C

37° C

37° C

37° C

37° C

Reaction pH

10.5 &
7.4

10.5

10.5

7.4

10.5

10.5

9.5

Reaction Buffer

Tris-Base

Tris-Base

Tris-Base

Tris-Base

Tris-Base

HEPES

Borate

Sample
Agitation

NO

NO

NO

5 RPM
Rotation

5 RPM
Rotation

5 RPM
Rotation

5 RPM
Rotation
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Table 2
Allergoid synthesis reagent candidates not effective in promoting a reaction with Ara h 2.

(+) indicates positive reaction and (–) indicates no reaction.
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Table 3
Allergoid synthesis reagent candidates effective promoting a reaction with Ara h 2.

(+) indicates positive reaction and (–) indicates no reaction.
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Centrifuge tubes were used to prepare the protein modification reactions. The
desired volume of reagent was added to an equal volume of protein to start the allergoid
reaction. The reaction solutions were incubated and agitated for 30 days at 37° C.
Reactions were carried out in a rotating incubator rotating 360 degrees at a speed of 5
RPM. After the desired time had passed, samples were evaluated by SDS-PAGE.
Excess modification reagent was removed by dialysis. Samples were dialyzed
against 3L of 15mM ammonium bicarbonate buffer at pH 7.4 in a 0.1 - 0.5 mL dialysis
cassette (MWCO 20kDa). Using a 1 mL syringe, separate dialysis cassettes were
individually loaded with modifications samples at different reagent concentrations until
all concentrations had been effectively dialyzed. Dialysis buffer exchanges were carried
out until samples appeared clear in color and no longer exhibited the original reagent
influenced color. Once modifying reagents were removed from the sample, modified
protein samples were lyophilized and stored at -70° C.
Results
According to Lundblad47 borate buffer at “basic pH” should facilitate protein
crosslinking reactions when solubilized proteins are exposed to diketone crosslinking
reagents. However, this is not reflected in our data. Figure 8 displays several SDS-PAGE
gels of unsuccessful allergoid reactions using borate buffer at different concentrations of
reagent. This is significant because literature has cited borate buffer as being an effective
buffer that should be used in protein modification reactions when using the reagents that
were used here.
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Ara h 2 was exposed to varying concentrations of Phenylglyoxal monohydrate, 4Fluorophenylglyoxal hydrate, 4-methoxyphenylgyoxal hydrate, 2,3-Butandione, 2,3Hexandione, 3,4-Hexanedione, and 2,3-Heptanedione. Allergoids were reproducibly
produced by using Tris-base buffer at pH 10.5 and sample agitation at 5 RPM by
rotisserie at 37° C.

Instead of the usual doublet band observation around 17kDa and

19kDa (in the case of native un-modified Ara h 2) a smearing pattern occurred between
and around the doublet bands which indicated some degree of protein modification to the
allergen monomer. In addition to the simple allergen protein modifications, where the
monomer was still the only oligomer present, the results of higher intensity modification
reactions were also observed. These high intensity reactions resulted in an observed
possible crosslink between allergen proteins by the formation of multiple oligomers,
appearing on the SDS-PAGE as dimers and even trimers as shown in Figure 9.
Discussions
The potential allergoid, the new product formed between Ara h 2 and the
modification reagent, is prepared in aqueous buffers. The reaction solution is a mixture of
the newly formed allergoid, un-reacted Ara h 2, reaction buffer, and reagent dissolving
solvent. Ara h 2 is an aqueous soluble protein, however most of the modification reagents
used were not soluble in water, so a range of solvents were needed to dissolved and
expose these reagents. Some of the reagents evaluated did not react well with Ara h 2,
this failure in reactivity may be attributed to reagent solubility or an incompatibility
between the solvents used and the reagent.
To determine which reaction conditions consistently produced a positive potential
allergoid formation, from natural Ara h 2 allergen, variations of these conditions were
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examined. However, for consistent results we found that using a simple 25 mM Tris-base
buffer worked well.
Most of the reagents used were completely insoluble in water based buffers, so
organic solvents were necessary. However, to avoid damaging or altering the Ara h 2
protein through the use of organic solvents alone it was also necessary to use the least
amount of solvent needed to fully dissolve the reagent in the buffer solution. To do this,
several trials were prepared where a fixed amount of crosslinking/modification reagent
was weighed out and then dissolved in the lowest possible volume of a solvent, finally
buffer was added to the reagent-solvent mixture to determine if the reagent would remain
soluble. Frequently the reagent used would precipitate of the solution after being mixed
with the buffer. After several attempts to determine the solubility of the desired reagent
quantity, varying the concentrations of reagent and organic solvents used (for each
reagent evaluated), the minimum amount of organic solvent required to solubilize the
reagent was determined. After this was determined we could then add the reagent to the
protein and begin the modification procedure.
Previously it was determined that agitation during incubation with the
crosslinking reagent was important for efficient reactivity. The reactor used in the lab was
constructed from a rotisserie style incubator device, allowing control of reaction
temperature. High temperatures are well known to increase the likelihood of collisions
between reacting molecules in solution, we found that incubating at 37 degrees Celsius
on a constant rotation speed of 5 RPM produced consistent reaction outcomes. The
rotating reactor allowed for the modification reaction to occur in a much shorter duration
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of time, which proved to be much more efficient and even more effective than the stand
alone stationary incubator.
Several reagents were attempted for allergoid synthesis potential and the complete
list can be found in Table 2 and Table 3. However, phenylglyoxal monohydrate
derivatives and simple diketone containing molecules were ultimately identified to
generate strong chemical crosslinking of Ara h 2. Based on these results, Ara h 2
modified with these reagents were further investigated for immunoreactivity with IgE and
IgG.

Figure 7. Methods for dissolving allergoid synthesis reagent candidate compounds in

polar buffers. Only candidates effective at promoting reactions with Ara h 2 are
displayed.
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Figure 8. SDS-PAGE of allergoid synthesis reagent candidates using borate buffer under
basic pH conditions.
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Figure 9. SDS-PAGE of successful allergoid synthesis reactions, reacted under basic
conditions in 25mM tris buffer.
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Chapter 4
Allergoid Viability Determination by In-Vitro Assay
A modified protein sample that displays a shift in mobility observed by SDSPAGE is a necessary initial confirmation that the protein sample deserves further
evaluation for its immune affinity. Unfortunately, however, a shift in mobility is not
sufficient to identify a modified allergen protein as a potential and useful allergoid.
Further experiments are required before any assumptions can be made about the sample.
Using specialized experiments founded in immunology, it may be possible to further
interpret if a potential allergoid product was actually formed. Immunoassays specific to
the native allergen are necessary to provide additional characterization details for the
allergoid. These details could include chemical and biological properties.
An appropriate immunoassay to determine the viability of the formed allergoid is
a western blot analysis. Western blot exposes the modified allergen to peanut specific IgE
antibodies to evaluate binding affinity. This immunoassay is based on the understanding
that IgE antibodies bind to regional protein epitopes that are intact and unshielded.
Variations to protein solubility can result in alterations to these epitope surfaces, possibly
due to exchanges between non-polar amino acids and polar amino acids. Surface IgE
epitopes that are disrupted or shielded, through chemical modification, could result in
decreased antibody binding affinity. In other words, if there is an observed difference in
binding affinity between the native allergen and that which was modified then antibodies
failed to bind to the modified allergen, and therefore resulted in the successful formation
of a potential allergoid.
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Materials and Methods
Preparing pAb for Western Blot analysis
Our research lab prepared the allergen sample provided to Neo Scientific to raise
and purify Ara h 2 specific IgE antibodies. IgE antibodies were raised against antigen
protein Ara h 2 in rabbits to be used in immunoassays. Antigen samples need to be
approximately 88% pure when raising IgE antibodies to avoid the potential of raising
antibodies against unknown impurities which could weaken overall affinity to Ara h 2.
Once the antigen is prepared and the purity is verified, using SDS-PAGE, the antigen can
then be exposed to rabbit organisms. Approximately 3-4 mL of antigen at a concentration
of 1-2 mg/mL is needed to prepare the antibodies. This is the process known as
sensitizing, since the antibodies are being sensitized to the antigen. The antigen is
exposed to the endogenous immune system of rabbits to form sensitized IgE antibodies.
After antibody sensitization, the animal is stimulated to produce IgE antibodies in the
presence of the allergen protein. Antibodies can then be removed simply by extracting
the animal’s blood and following up with a series of centrifuge purifications. The impure
antibody solution is then run on an affinity column to purify and collect only the desired
antibodies. Finally, a standard curve is used to determine antibody affinity toward the
antigen protein.
Western Blot Procedure
Prior to running the western blot analysis, an SDS-PAGE was completed where
replicates of the evaluated samples were prepared and run on the same SDS-PAGE gel.
The first half of the SDS-PAGE gel (lanes 1-6) contained replicate samples of the second
half of the gel (lanes 7-12). The SDS-PAGE gel was prepared in this way for the purpose
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of (after electrophoresis) exposing half of the gel to coomassie dye stain and half of the
gel to western blot analysis to eliminate the possibility of any variations between the two
samples. After successfully running the SDS-PAGE, the proteins were transferred from
gel to a cellulose membrane using the semi-dry western blotting technique. To start, 2
extra thick blotting pads and the cellulose membrane were exposed to transfer buffer (25
mM Tris buffer, 190 mM glycine, 20% methanol, dH2O to 1000 mL) for 15 minutes. The
gel was secured on top of the cellulose membrane between two blotting pads.
Sandwiching the samples to be transferred, the cathode plate assembly was secured to the
anode plate. The trans-blot semidry apparatus was run for 60 minutes at 15V. The
cellulose membrane was removed first washed with distilled water prior to being
immediately exposed to 5% stopping buffer (5% low fat milk in PBST) agitated at room
temperature for 60 minutes. The cellulose membrane was then washed 5 times with PBST for about 5 minutes each. The membrane was exposed to 10 mL of 1:250 primary IgE
antibody in 5% stopping buffer and agitated overnight at 4o C. Membrane was then
washed 5 times with PBS-T for about 5 minutes each. The membrane was then exposed
to 10 mL of 1:1000 secondary antibody in 5% stopping buffer and agitated at room
temperature for 60 minutes. Membrane then was washed 5 times with PBS-T for about 5
minutes each. The membrane was then immediately exposed to 5 mL of
chemiluminescence substrate. Substrate components were pre-prepared by the
manufacturer (ThermoFisher). Substrate components consisted of “Substrate A” and
“Substrate B” which needed to be mixed together prior to exposing to the membrane.
Substrate A and B were mixed equally, totaling 10 mL. Exposed membrane was then
incubated for 1 minute at room temperature (exposed to substrate). Photo of western blot
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was captured using a CD chemi-blot UV camera at normal intensity settings and 30
seconds exposure.
Results
Experiments were completed that exposed IgE antibodies to modified and
unmodified Ara h 2 to observe if there were any variations in antibody affinity. Figure 10
displays SDS-PAGE and western blot results of reagent exposed Ara h 2 samples. There
appears to be visible indication of protein chemical modification of Ara h 2 through
mobility shift observed by SDS-PAGE analysis. This figure appears to display visible
smearing and even polymerization dependent on the reagent used. There also appears to
be a direct correlation between higher reagent concentration exposure and an increased
susceptibility for the protein to undergo chemical modification. Higher concentrations of
exposed reagents modified Ara h 2 at higher intensities compared to lower reagent
concentrations. Western blot analysis of the samples appeared to display decreased
affinity of IgE antibodies toward the modified Ara h 2 allergen samples. Antibody
affinity also appeared to be dependent on the concentration of reagent exposed to the Ara
h 2 protein.
Discussions
As we experimented with chemical modifications to Ara h 2 and compared the
results of formed potential allergoids and unmodified allergens we noticed a visible
mobility shift by SDS-PAGE that directly correlated with a change in IgE antibody
binding affinity (Figure 10). A control using bovine serum albumin (BSA) was used to
identify any imprecise antibody binding and showed to be conclusive in that the
antibodies were actually specific to Ara h 2. Unmodified Ara h 2 was also used as a
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control to show the effectiveness of the antibody binding. Figure 10 displays a mobility
shift of modified Ara h 2, the modified allergen is still visible on the SDS-PAGE even
after being modified by the specific reagent. However, the western blot analysis shows a
stark difference between the antibody affinity towards the unmodified control and the
affinity towards the modified samples. This is evidence that the allergen protein is still
present in the sample solution but is failed to be detected by the highly specific
antibodies.
As Ara h 2 is modified there is a chance of losing the original protein solubility
character
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. SDS-PAGE cannot determine protein solubility specifically, but a lack of

visible protein on the SDS-PAGE, especially after protein modification, could be the
consequence of poorly dissolved protein as a result of the chemical modification. The
protein allergoid could potentially become so insoluble (compared to the native unmodified protein) that it could form an aggregate pellet and precipitate out of the sample
solution
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. If the protein does become so insoluble that it is no longer observable by

SDS-PAGE, and therefore western blot, attempts to solubilize the protein may be
necessary so it can be observed by SDS-PAGE and therefore able to be analyzed by
western blot. The idea that modified Ara h 2 could be less soluble in solution than the
native Ara h 2 was a reasonable consideration. However, due to time limitations and
extreme limitations on resources, specifically scarce quantities of allergen protein it was
not possible for us to perform experiments to fully test this argument.
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Figure 10. SDS-PAGE and ant-Ara h 2 IgE western blot of successful allergoid synthesis
reactions, reacted under basic conditions in 25mM Tris buffer.
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Chapter 5
Overall Allergen Crosslinking Discussion
Peanut protein Ara h 2 has been observed to produce severe allergic responses
when exposed to endogenous antibodies. Life-threatening conditions such as anaphylaxis
could be the result in allergic individuals who are not treated immediately after allergen
exposure. Currently, there is little that can be done to preemptively treat allergic episodes
resulting from peanut allergens. More research is necessary to increase understanding of
the complete role of the peanut allergen and its effects in the body. Identifying a safe
method of allergen exposure to patients could result in an endogenous immune system
tolerated to peanuts, and specifically the major peanut allergen Ara h 2.
The major allergen Ara h 2 was isolated successfully following the procedure
described in chapter 2. Several reaction conditions were attempted, listed in chapter 3.
The variables of these conditions that were mostly responsible for generating a positive
chemical modification reaction with Ara h 2 were determined. Tris-base buffer at 10.5
pH and at temperature of 37° C on constant rotation facilitated the reaction well. The
allergoid reaction procedure was then standardized to maintain consistency in reagent
target screening which allowed for reproducibility and resulted in the identification of
several vaccine candidate lead compounds. Several novel Ara h 2 allergoid synthesis
reaction mechanisms were proposed. Since the presence of epitope surfaces are the result
of the native protein structure, a significant disruption to this structure could lead
inaccessible or even eliminated epitope surface regions. Protein chemical modification
was the chief method used to alter the protein structure. According to Feeney50 protein
chemical modification is an effective method for altering protein structure. Reagents
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known to react with specific amino acids were used to promote the protein chemical
modification. SDS-PAGE was used to determine if the chemical modification was
successful.
As for protein chemical modification experiments, specifically when using SDSPAGE to observe results, the evaluated sample protein may appear at a molecular weight
different from the native protein, if there is a shift in gel mobility of the protein from the
native control sample then this could be the first observation of polymerization of the
protein. Even though it may be too soon to make any type of determination having only
molecular weight data, the data is still important because of the provided opportunity to
secure the polymerized samples to be further evaluated using additional experiments that
could lead to an enhanced understanding of the chemical properties of Ara h 2.
There were a few significant factors to keep in mind in our attempts to modify the
allergen. There was always a possibility of altering the allergen’s solubility when
synthesizing the allergoid thus causing the potentially formed allergoid to be insoluble.
Solubility changes appeared to occur more quickly at higher reagent concentrations.
Protein concentration, modification reagent concentration, and reaction conditions with
each concentration were evaluated thoroughly and in duplicates to determine the most
effective and direct route to a viable allergoid synthesis. There appeared to be
relationship between the quantity of reagents used and the overall strength of the
chemical modification to protein. Ultimately, protein concentrations around 1-2mg/mL
and chemical reagent concentrations around 50mM appeared to be the most effective in
modifying Ara h 2. In addition to reagent concentrations, higher pH and warmer
temperatures appeared to increase the likelihood of a potentially successful reaction.
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SDS-PAGE was the most effective technique available to us to identify protein
modification and the viability of the modification at the conditions being tested. There
always existed the possibility of only partially modifying Ara h 2, resulting in a modified
allergen protein that still retained IgE excitability potential. Therefore, the attempted
reaction conditions needed to be well refined to successfully facilitate the desired
allergoid forming reaction.
Another important consideration was the solvent (or solvents) used to dissolve
reagents within the buffer which were limited to a minimum so not to interfere with the
crosslinking reaction and to avoid any negative and destructive effects to the allergen as a
whole. The buffer used to maintain the reaction pH was based on the conditions essential
to the reagent being tested and if Ara h 2 could be safely stored in the specific buffer over
the duration of time needed to carry out the reaction.
The validity of the allergen modification reaction was first confirmed through
mobility shifts that suggested a change in protein molecular weight between the native
allergen and the allergen exposed to the evaluated compound. The change in molecular
weight is the initial indicator of a potential change to the epitope surface regions. A
positive change to the epitope surface regions is presumed to be indicative of a change in
immune-reactivity as well. A change in immunoreactivity could potentially result in a
change in how the allergen functions during in-vitro and in-vivo testing. Several
modification reagents were attempted, the complete list can be found in Table 2 and
Table 3, however the reagents capable of generating an actual allergoid are discussed in
further detail here. According to Packer35 proteins capable of crosslinking by chemical
modification to arginine residues contain roughly 5% arginine. The quantity of arginine
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residues in Ara h 2 is approximately 12%. The ketone aldehyde group of the compound
Phenylglyoxal acts as an oxidizing agent and targets arginine residues in proteins. The
guanidine group of arginine interacts with phenylglyoxal and forms heterocyclic
condensation products promoting a structural change to occur in Ara h 2 which results in
the crosslinking between two reactive Ara h 2 proteins. Diketone reacting groups of
simple organic molecules also react well with arginine amino acids and have been studied
to promote crosslinking in proteins 35.
Since phenylglyoxal monohydrate was previously determined to chemically
crosslink proteins at arginine residues when prepared at pH 10.5, and phenylglyoxal
monohydrate displayed crosslinking capabilities when exposed to Ara h 2, 4Fluorophenylglyoxal

hydrate,

3,4-difluorophenylglyoxal

hydrate,

4-

methoxyphenylgyoxal hydrate appeared to be good candidates as well for crosslinking
peanut allergen. Our successful attempts led us to our current understanding that 4Fluorophenylglyoxal

hydrate

and

3,4-difluorophenylglyoxal

hydrate

could

be

crosslinking Ara h 2 proteins in the same fashion as phenylglyoxal monohydrate where
the Fluorine(s) group on the aromatic ring could be acting as an electron withdrawing
group. It could be essential to pull electrons away from the diketone to react effectively to
Ara h 2. Another explanation could be how effectively the reagents were dissolved in the
reaction buffer. Each of these reagents was different in terms of solubility which could
have played a role in overall reactivity as well. There is currently no prior works using 4Flurophenylglyoxal hydrate in modifying the peanut allergen protein Ara h 2. No
associated IgE data could be obtained for 3,4-difluorophenylglyoxal hydrate, due to the
sample limit in the end. There was no 45 day SDS-PAGE data or IgE data to evaluate,
46

however this modification reagent was effective in modifying Ara h 2 after observing the
results of resulting sample batches that were completed at another time using a different
native Ara h 2 sample.
To expand our understanding of the importance of a diketone reacting group in
performing allergoid synthesis reactions with Ara h 2, 2,3-Butandione, 2,3-Hexandione,
3,4-Hexanedione, and 2,3-Heptanedione were evaluated. Currently there are no prior
works identifying the ability of these reagents to modify the peanut allergen protein Ara h
2. Each reagent displayed strong evidence of crosslinking, however 2,3-Hexandione was
observed to be the most effective reagent to crosslink Ara h 2. Our successful attempts
led us to the understanding that 2,3-Butandione, 2,3-Hexandione, 3,4-Hexanedione, 2,3Heptanedione and therefore the diketone group in phenylglyoxal could be essential in
crosslinking Ara h 2 through glycol and glycosylation reactions. It should also be noted
that O’Hehir48 claimed in their patent potential success in crosslinking Ara h 2 using
Phenylglyoxal, 2,3-Butandione, and 2,3-Hexandione, however no scientific studies could
be located to support this claim until now.
It is also worth noting that aside from the 2nd derivative series evaluated there
were 2 additional reagents evaluated that displayed evidence of crosslinking as well. The
reagents were Aurintricarboxylic acid and ethyl 2,3-dihydroxybenzoate. Further research
into the reason for modification with Aurintricarboxylic acid and ethyl 2,3dihydroxybenzoate is suggested since time prevented any further derivatives of these
reagents from being evaluated. However, 2,3-dihydroxybenzoate contains a quinone
group and successful reaction with Ara h 2 was observed in above 10.5 pH which is
consistent with the reaction conditions and mechanism proposed by Chung46.
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In-vitro immunoassays were also successfully performed and yielded results
consistent with the degree of observable allergen structural change. A direct correlation
was observed between the protein shift in mobility (observed by SDS-PAGE) and the
concentration of the reaction compound used. According to Figure 10 all reagents tested
appeared to successfully chemically modify Ara h 2 and physically disrupt epitope
regions as identified by western blot.
Several conditions were also evaluated to increase effectiveness during the initial
compound screening experiments and proved invaluable in increasing the rate of
identified hit compounds. The evaluated reaction conditions included variations in
reaction buffer, reaction buffer pH, exposing the reaction mixture to agitation vs. nonagitation, reaction temperature, concentration of reagent exposed to protein, and time
exposed to protein we all evaluated to understand which conditions were ultimately most
effective in forming an allergoid. To determine which reagent concentrations to use with
the protein a large range of concentrations was evaluated to identify where the extremes
were and to identify the potential working concentration. The apparent working reagent
concentration was determined to be between 25mM - 50mM. A standard range of
250mM - 1mM reagent concentration was frequently used to obtain the optimal working
range for each reagent examined. Upon identifying which reagents react with Ara h 2, it
is then necessary to make the fine-tune adjustments to optimize the allergoid where these
adjustments can even as extensive as acquiring the chemical derivatives for the molecules
being tested to determine the potential for stronger reactivity when compared to the
original parent molecule structure.
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Protein concentration was also important to remain as consistent as possible under
the circumstances so to only evaluate one variable at a given time. The desired working
protein concentration was around 1 – 2mg/mL, which was the seemingly effective
working concentration identified by past researchers who determined that a 5mg/mL
mixture of Ara h 2 and Ara h 6 was appropriate to modify Ara h 2 with phytic acid 49.
Conclusions
Moving forward we hope to increase our understanding of the allergoid chemical
structure as well as identifying if any therapeutic benefits exist. Further characterization
experiments are needed to better understand the allergoid structure, and to possibly make
further modification enhancements that could benefit the overall product. In addition to
characterization, higher order biological testing is also necessary to identify product
stability and to determine what possible therapeutic benefits this product is capable of. It
is also essential to provide further understanding for the allergoid theory in general,
which could ultimately yield more public support for research projects like this one.
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(a)

(b)

Figure 11. Ara h 2 crosslinking reaction mechanism. (a) Abbreviated Ara h 2 dimer and
trimer formation reaction using diketone reagents and phenylglyoxal derivative
compounds (only phenylglyoxal parent structure displayed here). (b) Phenylglyoxal
mediated Ara h 2 crosslinking reaction through accessible arginine residues producing a
crosslinking event between protein 1 and 2 (P1 and P2). In this schematic, reactants are
not to scale.
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